EU Agency Probes Safety Of Pfizer’s Champix

Law360, New York (December 17, 2007, 12:00 AM EST) -- The European Union’s medicine watchdog has opened an investigation into the safety of Pfizer Inc.’s Champix after alarming reports suggested risks of depression and suicide in patients using the anti-smoking treatment.

The European Medicines Agency, which authorizes drugs for the EU, asked Pfizer on Friday to turn over more information about the occurrences of depression and suicide in patients treated with Champix.

During a meeting this month, the agency said there was "a need to update the product information for Champix to warn doctors and patients...
To view the full article, register now.